Appointments at Morphotek and Qualitest and resignations at Sigma-Aldrich and GenVec – People on the move
Morphotek has appointed Joye Bramble as vice president (VP), pilot plant operations, giving her responsibility for management and operation of its new biologics production facility. Bramble most recently worked at Merck Research Labs, a company she joined in 1990.
David Julien is to retire as president, global supply chain at Sigma-Aldrich. Joseph Porwoll has been promoted to VP, global supply chain to takeover the responsibilities held by Julien.
Qualitest Pharmaceuticals has named Robert Mills as its president. Mills has more than 30 years of pharma experience which he gained working at Columbia Laboratories, Watson Pharmaceuticals, Schein Pharmaceuticals and Alpharma.
Mark Thornton has resigned from the position of SVP, product development at GenVec. Thornton worked at GenVec for three years but has now accepted position at another company.
Strativa Pharmaceuticals has promoted Melissa Masterson to the position of VP, managed markets. Masterson joined Strativa in 2006 having spent the previous 11 years at Forest Pharmaceuticals.
Mark Smith has resigned as chief financial officer of Sigma Pharmaceuticals a month after Elmo de Alwis, the then CEO, stepped down. John Stocker, chairman of Sigma, also intends to retire. Last week, South Africa-based Aspen offered A$1.5m ($1.2m) to acquire Sigma.
Oramed Pharmaceuticals has appointed Michael Berelowitz to its board of directors. Berelowitz is currently SVP and head of clinical development and medical affairs in the speciality care business unit at Pfizer. He has worked at Pfizer since 1996.
